Molecular Cancer,
Journal Year:
2022,
Volume and Issue:
21(1)
Published: Nov. 2, 2022
Tumors
are
comprised
of
both
cancer
cells
and
surrounding
stromal
components.
As
an
essential
part
the
tumor
microenvironment,
stroma
is
highly
dynamic,
heterogeneous
commonly
tumor-type
specific,
it
mainly
includes
noncellular
compositions
such
as
extracellular
matrix
unique
cancer-associated
vascular
system
well
a
wide
variety
cellular
components
including
activated
fibroblasts,
mesenchymal
cells,
pericytes.
All
these
elements
operate
with
each
other
in
coordinated
fashion
collectively
promote
initiation,
progression,
metastasis
therapeutic
resistance.
Over
past
few
decades,
numerous
studies
have
been
conducted
to
study
interaction
crosstalk
between
neoplastic
cells.
Meanwhile,
we
also
witnessed
exponential
increase
investigation
recognition
critical
roles
solid
tumors.
A
series
clinical
trials
targeting
launched
continually.
In
this
review,
introduce
discuss
current
advances
understanding
various
their
cancers.
We
elaborate
on
potential
novel
approaches
for
tumor-stroma-based
targeting,
aim
leap
from
bench
bedside.
Frontiers in Pharmacology,
Journal Year:
2023,
Volume and Issue:
14
Published: March 14, 2023
Cancer
immunotherapy
has
opened
a
new
landscape
in
cancer
treatment,
however,
the
poor
specificity
and
resistance
of
most
targeted
therapeutics
have
limited
their
therapeutic
efficacy.
In
recent
years,
role
CAFs
immune
regulation
been
increasingly
noted
as
more
evidence
uncovered
regarding
link
between
cancer-associated
fibroblasts
(CAFs)
evolutionary
process
tumor
progression.
interact
with
cells
to
shape
microenvironment
(TIME)
that
favors
malignant
progression,
crosstalk
leads
failure
immunotherapies.
this
review,
we
outline
advances
immunosuppressive
function
CAFs,
highlight
mechanisms
CAFs-immune
cell
interactions,
discuss
current
CAF-targeted
strategies
for
future
study.
International Journal of Nanomedicine,
Journal Year:
2024,
Volume and Issue:
Volume 19, P. 571 - 608
Published: Jan. 1, 2024
Abstract:
With
the
development
of
nanotechnology,
nanoparticles
(NPs)
have
shown
broad
prospects
as
drug
delivery
vehicles.
However,
they
exhibit
certain
limitations,
including
low
biocompatibility,
poor
physiological
stability,
rapid
clearance
from
body,
and
nonspecific
targeting,
which
hampered
their
clinical
application.
Therefore,
novel
systems
with
improved
biocompatibility
high
target
specificity
remains
a
major
challenge.
In
recent
years,
biofilm
mediated
biomimetic
nano-drug
system
(BNDDS)
has
become
research
hotspot
focus
in
field
life
sciences.
This
new
platform
uses
bio-nanotechnology
to
encapsulate
synthetic
NPswithin
membrane,
organically
integrating
immunogenicity,
toxicity,
tumor
good
adjustability
versatility
nanocarrier,
shows
promising
applications
precision
therapy.
this
review,
we
systematically
summarize
progress
BNDDS
used
for
optimizing
delivery,
providing
theoretical
reference
designing
safe
efficient
treatment
strategies
improve
outcomes.
Keywords:
nanoparticles,
cell
targeted
therapy
Frontiers in Molecular Biosciences,
Journal Year:
2024,
Volume and Issue:
11
Published: Feb. 22, 2024
The
tumor
microenvironment
(TME)
is
a
complex
ecosystem
of
cells,
signaling
molecules,
and
extracellular
matrix
components
that
profoundly
influence
cancer
progression.
Among
the
key
players
in
TME,
cancer-associated
fibroblasts
(CAFs)
have
gained
increasing
attention
for
their
diverse
influential
roles.
CAFs
are
activated
found
abundantly
within
TME
various
types.
contribute
significantly
to
progression
by
promoting
angiogenesis,
remodeling
matrix,
modulating
immune
cell
infiltration.
In
order
microenvironment,
engage
cross-talk
with
other
stromal
through
paracrine
direct
cell-cell
interactions.
This
can
result
immunosuppression,
proliferation,
epithelial-mesenchymal
transition,
contributing
disease
Emerging
evidence
suggests
play
crucial
role
therapy
resistance,
including
resistance
chemotherapy
radiotherapy.
modulate
response
treatment
secreting
factors
promote
drug
efflux,
enhance
DNA
repair
mechanisms,
suppress
apoptosis
pathways.
paper
aims
understand
multifaceted
functions
discusses
between
sheds
light
on
contibution
resistance.
Targeting
or
disrupting
cells
holds
promise
overcoming
improving
efficacy
iScience,
Journal Year:
2024,
Volume and Issue:
27(6), P. 109979 - 109979
Published: May 15, 2024
This
review
explores
the
hallmarks
of
cancer
resistance,
including
drug
efflux
mediated
by
ATP-binding
cassette
(ABC)
transporters,
metabolic
reprogramming
characterized
Warburg
effect,
and
dynamic
interplay
between
cells
mitochondria.
The
role
stem
(CSCs)
in
treatment
resistance
regulatory
influence
non-coding
RNAs,
such
as
long
RNAs
(lncRNAs),
microRNAs
(miRNAs),
circular
(circRNAs),
are
studied.
chapter
emphasizes
future
directions,
encompassing
advancements
immunotherapy,
strategies
to
counter
adaptive
integration
artificial
intelligence
for
predictive
modeling,
identification
biomarkers
personalized
treatment.
comprehensive
exploration
these
provides
a
foundation
innovative
therapeutic
approaches,
aiming
navigate
complex
landscape
enhance
patient
outcomes.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Nov. 21, 2024
Metabolic
alterations,
a
hallmark
of
cancer,
enable
tumor
cells
to
adapt
their
environment
by
modulating
glucose,
lipid,
and
amino
acid
metabolism,
which
fuels
rapid
growth
contributes
treatment
resistance.
In
primary
breast
metabolic
shifts
such
as
the
Warburg
effect
enhanced
lipid
synthesis
are
closely
linked
chemotherapy
failure.
Similarly,
metastatic
lesions
often
display
distinct
profiles
that
not
only
sustain
but
also
confer
resistance
targeted
therapies
immunotherapies.
The
review
emphasizes
two
major
aspects:
mechanisms
driving
in
both
how
unique
environments
sites
further
complicate
treatment.
By
targeting
vulnerabilities
at
stages,
new
strategies
could
improve
efficacy
existing
provide
better
outcomes
for
cancer
patients.
Cancers,
Journal Year:
2023,
Volume and Issue:
15(9), P. 2536 - 2536
Published: April 28, 2023
The
tumor
microenvironment
(TME)
plays
a
key
role
in
cancer
development
and
progression,
as
well
contributes
to
the
therapeutic
resistance
metastasis
of
cells.
TME
is
heterogeneous
consists
multiple
cell
types,
including
cancer-associated
fibroblasts
(CAFs),
endothelial
cells,
immune
various
extracellular
components.
Recent
studies
have
revealed
cross
talk
between
cells
CAFs
other
Signaling
by
transforming
growth
factor-β,
derived
from
CAFs,
has
recently
been
shown
induce
remodeling
tissue,
promotion
angiogenesis
recruitment.
Immunocompetent
mouse
models
that
recapitulate
interactions
with
provided
insight
into
network
support
new
anticancer
strategies.
based
on
such
antitumor
action
molecularly
targeted
agents
mediated
part
effects
environment.
In
this
review,
we
focus
cell–TME
provide
an
overview
basis
for
strategies
target
TME,
immunotherapy.
